Search our Database of Scientific Publications and Authors

I’m looking for a

    2020 results match your criteria Angioimmunoblastic Lymphoma

    1 OF 41

    Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.
    Cell Immunol 2017 Jul 10. Epub 2017 Jul 10.
    Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address:
    CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. Read More

    Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.
    J Clin Invest 2017 Jul 10. Epub 2017 Jul 10.
    Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology and.
    Angioimmunoblastic T cell lymphoma (AITL) represents a distinct, aggressive form of peripheral T cell lymphoma with a dismal prognosis. Recent exome sequencing in patients with AITL has revealed the frequent coexistence of somatic mutations in the Rho GTPase RhoA (RhoAG17V) and loss-of-function mutations in the 5-methylcytosine oxidase TET2. Here, we have demonstrated that TET2 loss and RhoAG17V expression in mature murine T cells cooperatively cause abnormal CD4+ T cell proliferation and differentiation by perturbing FoxO1 gene expression, phosphorylation, and subcellular localization, an abnormality that is also detected in human primary AITL tumor samples. Read More

    Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma.
    Ann Hematol 2017 Jun 20. Epub 2017 Jun 20.
    Department of Hematology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
    Recent genetic studies identified that the disease-specific G17V RHOA mutation, together with mutations in TET2, DNMT3A, and IDH2, is a hallmark of angioimmunoblastic T cell lymphomas (AITL). The diagnostic value of these mutations is now being investigated. Circulating tumor DNAs (ctDNAs) may offer a non-invasive testing for diagnosis and disease monitoring of cancers. Read More

    Profiling of peripheral T-cell lymphomas in Kerala, South India: A 5-year study.
    Indian J Pathol Microbiol 2017 Apr-Jun;60(2):206-208
    Division of Pathology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
    Background: Peripheral T-cell lymphomas (PTCLs) are non-Hodgkin's lymphomas (NHLs) with considerable variation in incidence across the world. They show a wide variety of clinicopathological features and generally associated with poor clinical outcome. Lymphoma data from different geographic regions will definitely aid in routine clinical practice and research work. Read More

    Treatment of Peripheral T-Cell Lymphoma in Community Settings.
    Clin Lymphoma Myeloma Leuk 2017 Jun 10;17(6):354-361. Epub 2017 May 10.
    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; COTA Inc, New York, NY. Electronic address:
    Background: Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies that do not have consensus treatment recommendations. Strategies extrapolated from B-cell lymphoma have met with limited efficacy, although T-cell-specific salvage therapies have been recently developed.

    Methods: To determine treatment patterns and associated outcomes in PTCL not otherwise specified (PTCL-NOS), anaplastic large T-cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL), a retrospective analysis was undertaken at a large US community oncology network among patients treated between January 2010 and April 2015. Read More

    Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome).
    Case Rep Dermatol 2017 Jan-Apr;9(1):74-79. Epub 2017 Mar 21.
    aDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
    Angioimmunoblastic T-cell lymphoma (AITCL) is a rare, aggressive lymphoma which derives from follicular helper T cells, commonly affecting the elderly population. It accounts for 2% of all non-Hodgkin lymphomas, with a reported 5-year overall survival rate of less than 30%. Very often, the clinical picture of AITCL encompasses systemic symptoms such as generalized lymphadenopathy, hepatosplenomegaly, skin rash, anemia, and polyclonal hypergammaglobulinemia. Read More

    Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification.
    J Pathol Transl Med 2017 Jun 5. Epub 2017 Jun 5.
    Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
    Epstein-Barr virus (human herpesvirus-4) is very common virus that can be detected in more than 95% of the human population. Most people are asymptomatic and live their entire lives in a chronically infected state (IgG positive). However, in some populations, the Epstein-Barr virus (EBV) has been involved in the occurrence of a wide range of B-cell lymphoproliferative disorders (LPDs), including Burkitt lymphoma, classic Hodgkin's lymphoma, and immune-deficiency associated LPDs (post-transplant and human immunodeficiency virus-associated LPDs). Read More

    Death caused by possible unrecognized (too Late Recognized) Mycobacterium gordonae infection in a patient with angioimmunoblastic T-cell lymphoma.
    Int J Mycobacteriol 2017 Apr-Jun;6(2):199-201
    Department of Hematology and Oncology, General Hospital Dr. Josip Benčević, Andrije Štampara 42, Slavonski Brod 35000, Croatia.
    Here, we present possible death caused by Mycobacterium gordonae infection in a patient with angioimmunoblastic T-cell lymphoma. Our patient was severely immunocompromised in whom we suspect to an infection, but we did not have isolates until she died. After she died, we received a positive sputum culture of M. Read More

    Unusual Histology in Hodgkin's Lymphoma: Report of an Interesting Case.
    Indian J Surg Oncol 2017 Jun 9;8(2):181-184. Epub 2016 Dec 9.
    Hamdard Institute of Medical Sciences and Research (HIMSR), New Delhi, India.
    Hodgkin's lymphoma has a significant presence in the Indian subcontinent. Microscopically, the hallmark of Hodgkin's lymphoma (HL) is the Hodgkin and Reed-Sternberg (HRS) cell, which is usually surrounded by a cellular infiltrate of non-malignant inflammatory cells that constitute the majority of the tumor tissue. Cells which are known to be histologic mimics of HRS cells include immunoblasts, plasmablasts and rarely dendritic cells. Read More

    Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells.
    J Pathol 2017 Aug 29;242(4):387-390. Epub 2017 Jun 29.
    Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
    Angioimmunoblastic T-cell lymphoma (AITL) is one of the most frequent entities of peripheral T-cell lymphoma. An AITL has two components: the AITL tumour cells, which have a T follicular helper (TFH) cell phenotype, and a surrounding and extensive tumour microenvironment that is populated with various reactive cell types, including B cells. Recurrent TET2 mutations have been described in 50-80% of AITLs, possibly occurring in a haematopoietic progenitor cell. Read More

    IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.
    J Cancer 2017 29;8(6):1018-1024. Epub 2017 Mar 29.
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    Background: Interferon regulatory factor 4 (IRF4)/multiple myeloma oncogene-1 (MUM1) is a member of the interferon regulatory factor family of transcriptional factors. Although IRF4/MUM1 expression is associated with aggressiveness of B-cell lymphoma and multiple myeloma, the prognostic value of IRF4/MUM1 expression in peripheral T-cell lymphoma (PTCL) is unclear. Methods: We analyzed a tissue array from 69 patients diagnosed with PTCL. Read More

    The aggressive peripheral T-cell lymphomas: 2017.
    Am J Hematol 2017 Jul;92(7):706-715
    The Joe Shapiro Professor of Medicine, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha, NE, 68198.
    Background: T-cell lymphomas make up approximately 10%-15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.

    Diagnosis: The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the World Health Organization classification. Read More

    Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.
    Front Oncol 2017 2;7:86. Epub 2017 May 2.
    Department of Biology, University of Nebraska at Omaha, Omaha, NE, USA.
    The role of the tumor microenvironment in leukemias and lymphomas is well established, yet the intricacies of how the malignant cells regulate and influence their non-malignant counterparts remain elusive. For example, chronic lymphocytic leukemia (CLL) is an expansion of malignant CD5(+)CD19(+) B cells, yet the non-malignant T cells play just as large of a role in disease presentation and etiology. Herein, we review the dynamic tumor cell to lymphoid repertoire interactions found in two non-Hodgkin's lymphoma subtypes: CLL and angioimmunoblastic T-cell lymphoma. Read More

    A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax.
    Case Rep Hematol 2017 12;2017:1279525. Epub 2017 Apr 12.
    Department of Pathology, VieCuri Medical Centre, 5912 BL Venlo, Netherlands.
    Angioimmunoblastic T-cell lymphoma is a rare non-Hodgkin lymphoma with dismal prognosis. The median age of presentation ranges from 62 to 69 years with generalized lymphadenopathy, B symptoms, and hepatosplenomegaly as the most prevalent symptoms. The combination of B-cell and T-cell proliferations is common in AITL and the B-cell component may resemble Reed-Sternberg-like B-cells. Read More

    Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma.
    Heart Surg Forum 2017 Mar 6;20(2):E043-E044. Epub 2017 Mar 6.
    Peking Union Medicine School Hospital, Cardiac Surgery Department, Peking.
    A 21-year-old man presented initially with impending cardiac tamponade secondary to an angioimmunoblastic T-cell lymphoma (AITL). Following unsuccessful pericardiocentesis and subxiphoid pericardiostomy, the patient's deteriorating hemodynamics prompted an urgent sternotomy. Histopathological diagnosis confirmed AITL. Read More

    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol 2017 Jun 1;35(18):2008-2017. Epub 2017 May 1.
    Camille Laurent, Nadia Amara, Georges Delsol, and Pierre Brousset, Institut Universitaire du Cancer-Oncopole de Toulouse; Centre Hospitalier Universitaire (CHU) Toulouse; Camille Laurent, Georges Delsol, and Pierre Brousset, Institut National de la Santé et de la Recherche Médicale (INSERM), U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, Laboratoire d'Excellence Toulouse Cancer; Thomas Filleron, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse, Toulouse; Marine Baron, Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier; Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, INSERM U955, Université Paris-Est, Créteil; Mylène Dandoit, Marc Maynadié, and Laurent Martin, CHU de Dijon, Dijon; Marie Parrens, Beatrice Vergier, and Antoine de Mascarel, Hôpital du Haut Lévêque, CHU de Bordeaux, Bordeaux; Bettina Fabiani, AP-HP, Hôpital Saint-Antoine; Nicole Brousse and Thierry Jo Molina, AP-HP, Hôpital Necker; Josette Brière, AP-HP, Hôpital Saint Louis; Fréderic Charlotte, AP-HP, Hôpital Pitié Salpétrière; Diane Damotte, AP-HP, Hôpitaux Universitaires Paris Centre, Paris; Alexandra Traverse-Glehen and Françoise Berger, CHU Lyon-Sud; Catherine Chassagne-Clement, Centre Léon Bérard, Lyon; Marie-Christine Copin, Univ Lille, CHU Lille, Lille; Patrick Tas, CHU de Rennes, Rennes; Marie-Christine Rousselet, CHU d'Angers, Angers; Thérèse Rousset, Hôpital Gui de Chauliac, CHU de Montpellier, Montpellier; Luc Xerri, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille; Anne Moreau and Céline Bossard, Hôpital Hôtel Dieu, CHU de Nantes, Nantes; Antoine Martin, Hôpital Avicenne, Bobigny, Bobigny; Peggy Dartigues, Institut Gustave Roussy, Villejuif; Isabelle Soubeyran, Institut Bergonié, Bordeaux; Michel Peoch, CHU de Saint Etienne, Saint Etienne; Pierre Dechelotte, CHU de Clermont-Ferrand, Clermont-Ferrand; Jean-François Michiels, CHU de Nice, Nice; Flavie Arbion, CHU de Tours, Tours; Isabelle Quintin-Roué, CHU de Brest, Brest; Jean-Michel Picquenot, Centre Henri Becquerel, CHU de Rouen, Rouen; Martine Patey, CHU de Reims, Reims; Blandine Fabre, CHU de Grenoble, Grenoble; Henri Sevestre, CHU d'Amiens, Amiens; Cécile Le Naoures, CHU de Caen, Caen; Marie-Pierre Chenard-Neu, CHU de Strasbourg, Strasbourg; Claire Bastien, CHU de Nancy, Nancy; Sylvie Thiebault, CH de Mulhouse, Mulhouse; Manuela Delage, CHU de Limoges, Limoges; Gilles Salles, Hospices Civils de Lyon, CHU Lyon-Sud; Gilles Salles, INSERM1052, Centre National de la Recherche Scientifique 5286, Université Claude Bernard, Pierre Bénite, France; Tony Petrella, Pathology University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada.
    Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network. Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care. Read More

    Angioimmunoblastic T Cell lymphoma mimics reactive lymphoid tissue on cytomorphology: A multimodality approach utilising cytology, immunocytochemistry and flow cytometry to resolve this diagnostic dilemma.
    Cytopathology 2017 Jun 28;28(3):239-241. Epub 2017 Mar 28.
    Manchester Cytology Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK.

    Uncommon Variants of T-Cell Lymphomas.
    Hematol Oncol Clin North Am 2017 Apr;31(2):285-295
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill-Cornell Medical College, 1233 York Avenue, New York, NY 10022, USA. Electronic address:
    Peripheral T-cell lymphomas represent 10% to 15% of non-Hodgkin lymphomas and comprise more than 20 different entities. Treatment of very rare T-cell lymphomas can be challenging because there are no large or randomized studies to guide clinical decision making, and treatment paradigms are often based on small series or imperfect data. Although a strict algorithm cannot be written with certainty, through the literature that exists and clinical experience, themes and principles of approaches do emerge that when coupled with clinical judgment allow reasonable and logical decisions. Read More

    Angioimmunoblastic T-Cell Lymphoma.
    Hematol Oncol Clin North Am 2017 Apr;31(2):223-238
    Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti, 9, Bologna 40138, Italy. Electronic address:
    Angioimmunoblastic T-cell lymphoma is a follicular T-helper-derived neoplasm displaying a peculiar morphologic appearance and biological complexity. New mutations have been described that contribute to elucidating the underlying pathogenetic events. The disease behaves aggressively and typically affects elderly patients. Read More

    TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.
    J Pathol 2017 Jun 3;242(2):129-133. Epub 2017 May 3.
    Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, Essen, Germany.
    Angioimmunoblastic T-cell lymphomas (AITLs) frequently carry mutations in the TET2 and IDH2 genes. TET2 mutations represent early genetic lesions as they had already been detected in haematopoietic precursor cells of AITL patients. We show by analysis of whole-tissue sections and microdissected PD1(+) cells that the frequency of TET2-mutated AITL is presumably even higher than reported (12/13 cases in our collection; 92%). Read More

    The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma 2017 Oct 17;58(10):2349-2355. Epub 2017 Mar 17.
    a Fujian Provincial Key Laboratory on Hematology , Fujian Medical University Union Hospital, Fujian Institute of Hematology , Fuzhou , Fujian , China.
    The aim of the study was to determine the clinical significance of EBV DNA in the peripheral blood mononuclear cells (PBMCs) from the patients with non-Hodgkin lymphoma (NHL). Newly diagnosed patients with NHL were enrolled in the study (n = 328), and clinical data retrospectively analyzed. EBV DNA was detectable in 34. Read More

    Genetic Landscape and Classification of Peripheral T Cell Lymphomas.
    Curr Oncol Rep 2017 Apr;19(4):28
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
    Purpose Of Review: Peripheral T cell lymphomas (PTCLs) are markedly heterogeneous at the clinical, pathological, and molecular levels. This review will discuss genetic findings in PTCL with special emphasis on how they impact lymphoma classification.

    Recent Findings: Sequencing studies have identified recurrent genetic alterations in nearly every PTCL subtype. Read More

    Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol 2017 Mar 13;35(9):955-962. Epub 2017 Feb 13.
    Andrea B. Moffitt and Sandeep S. Dave, Duke University, Durham, NC.
    In this review, we examine the genomic landscapes of lymphomas that arise from B, T, and natural killer cells. Lymphomas represent a striking spectrum of clinical behaviors. Although some lymphomas are curable with standard therapy, the majority of the affected patients succumb to their disease. Read More

    Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    J Int Med Res 2017 Feb 12;45(1):290-302. Epub 2017 Jan 12.
    Peking Union Medical College Hospital (PUMCH), Beijing, China.
    Objective To determine the efficacy and prognosis of autologous hematopoietic stem cell transplantation (ASCT) as frontline treatment for peripheral T cell lymphoma (PTCL). Methods Clinical data from 46 PTCL patients who achieved complete (CR) or partial remission (PR) after ASCT from October 1996 to July 2014 were analysed retrospectively. Results Median patient age was 32 (range: 15-68) years. Read More

    Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
    Clin Lymphoma Myeloma Leuk 2017 Apr 10;17(4):193-200. Epub 2017 Jan 10.
    Department of Medical Oncology, Yale University, New Haven, CT.
    Background: With increased understanding of the unique entities, subtype-specific approaches for peripheral T-cell lymphoma (PTCL) are emerging, and more precise diagnoses are becoming increasingly important. PATIENTS AND METHODS: We analyzed the approach to the histopathologic diagnosis of PTCL using data from the comprehensive oncology measures of peripheral T-cell lymphoma (COMPLETE) study. The COMPLETE trial is a large prospective cohort study of patients with newly diagnosed PTCL in the United States. Read More

    Angioimmunoblastic T-Cell Lymphoma: A Questionable Association with Follicular Dendritic Cell Sarcoma.
    Case Rep Hematol 2017 18;2017:9601094. Epub 2017 Jan 18.
    Department of Pathology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
    An elderly woman presented with generalized lymphadenopathy, several systemic symptoms, and splenomegaly. An inguinal lymph node excision revealed a compound picture. One aspect of the lymph node morphology, including cells with follicular T-helper cell phenotype, was most consistent with angioimmunoblastic T-cell lymphoma. Read More

    Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma.
    Biomark Res 2017 8;5. Epub 2017 Feb 8.
    Department of Internal Medicine, Division of Hematology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
    Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common subtypes of peripheral T-cell lymphoma. Advances in understanding the mutational landscape of AITL have not resulted in improved prognosis nor consensus regarding optimal first-line and second-line treatment. The recently proposed multistep tumorigenesis model for AITL provides a theoretical framework of AITL oncogenesis. Read More

    Angioimmunoblastic T-Cell Lymphoma with Polyarthritis Resembling Rheumatoid Arthritis.
    Clin Med Res 2016 Dec;14(3-4):159-162
    Department of Pathology, Marshfield Clinic, Marshfield Wisconsin USA.
    Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma (PTCL). AITL typically presents with lymphadenopathy, fever, rash, hepatosplenomegaly, and rarely polyarthritis. We report the case of a 50-year-old female who presented with lymphadenopathy, rash, and symmetric polyarthritis. Read More

    Identification of cell-type-specific mutations in nodal T-cell lymphomas.
    Blood Cancer J 2017 Jan 6;7(1):e516. Epub 2017 Jan 6.
    Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
    Recent genetic analysis has identified frequent mutations in ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 2 (IDH2) and ras homolog family member A (RHOA) in nodal T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. We examined the distribution of mutations in these subtypes of mature T-/natural killer cell neoplasms to determine their clonal architecture. Targeted sequencing was performed for 71 genes in tumor-derived DNA of 87 cases. Read More

    Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.
    Oncotarget 2017 Mar;8(11):17763-17770
    Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
    Angioimmunoblastic T cell lymphoma (AITL) originates from follicular helper T-cells and is characterised by a polymorphic infiltrate with the neoplastic T-cells forming small clusters around the follicle and high endothelial venules. Despite the recent advances in its phenotypic characterisation, the genetics and molecular mechanisms underlying AITL are not fully understood. In the present study, we performed whole exome sequencing in 9 cases of AITL from Taiwan (n = 6) and U. Read More

    Chidamide in the treatment of peripheral T-cell lymphoma.
    Onco Targets Ther 2017 12;10:347-352. Epub 2017 Jan 12.
    Department of Medicine, Queen Mary Hospital, Hong Kong, People's Republic of China.
    Mature T-cell lymphomas are aggressive malignancies. Treatment outcome is poor with conventional chemotherapy. They are about twice as common in Asia as compared with other non-Asian countries. Read More

    Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.
    Expert Rev Hematol 2017 Mar 29;10(3):239-249. Epub 2017 Jan 29.
    a Department of Laboratory Medicine and Pathology , Mayo Clinic , Rochester , MN , USA.
    Introduction: Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Read More

    [A Case of Angioimmunoblastic T-Cell Lymphoma Merged with Colorectal Cancer That We Were Able to Resect after a Chemotherapy Response].
    Gan To Kagaku Ryoho 2016 Nov;43(12):1620-1622
    Dept. of Surgery, Minoh City Hospital.
    The patient was 77-year-old man. He visited our hospital with the chief complaint of an abdominal mass in March 2015. We diagnosed the patient with transverse colon cancer and he was suspected of having malignant lymphoma. Read More

    Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan.
    Am J Surg Pathol 2017 Apr;41(4):506-516
    *Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan †Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt ‡Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan §Department of Clinical Laboratory, Nagano Prefectural Suzaka Hospital, Nagano, Japan.
    The presence of Hodgkin and Reed-Sternberg (HRS)-like B-cells in peripheral T-cell lymphoma (PTCL) is rare and its clinicopathological features still remain unclear. Here, we describe 30 cases of PTCL with HRS-like B-cells from Japan. Twenty-three cases (77%) presented evidence of follicular T-helper phenotype (TFH) derivation: 12 were angioimmunoblastic T-cell lymphoma and 11 PTCL with TFH phenotype (PTCL-TFH). Read More

    Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.
    Blood 2017 Mar 23;129(9):1095-1102. Epub 2017 Jan 23.
    Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE.
    Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature would suggest given the many names that have preceded it. Advanced-stage disease is common with uncharacteristic laboratory and autoimmune findings that often slow or mask the diagnosis. Read More

    Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
    Mod Pathol 2017 May 13;30(5):734-744. Epub 2017 Jan 13.
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Langerhans cell histiocytosis is characterized by a localized or systemic proliferation of Langerhans cells. BRAF mutations have been reported in 40-70% of cases and MAP2K1 mutations have been found in BRAF-negative cases, supporting that Langerhans cell histiocytosis is a true neoplasm, at least in mutated cases. In a small subset of patients, Langerhans cell histiocytosis is detected incidentally in a biopsy involved by lymphoma. Read More

    Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma.
    Onco Targets Ther 2017 22;10:145-151. Epub 2016 Dec 22.
    Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
    Peripheral T cell lymphoma (PTCL) has a poor prognosis. Overexpression of vascular endothelial growth factor (VEGF) might contribute to the poor prognosis of PTCL and could be the target of novel therapy. The efficacy and safety of recombinant human endostatin (Endostar) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (ECHOP) have been explored in 15 PTCL patients. Read More

    Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy.
    Intern Med 2017;56(1):85-89. Epub 2017 Jan 1.
    Department of Internal Medicine, Nagano Chuo Hospital, Japan.
    Few cases of IgA nephropathy with angioimmunoblastic T-cell lymphoma (AITL) have been reported. We herein present the case of a 79-year-old Japanese man with AITL and IgA nephropathy. The patient presented with generalized edema, fatigue, and fever. Read More

    Cutaneous Presentation of Angioimmunoblastic T-Cell Lymphoma: A Harbinger of Poor Prognosis?
    Skinmed 2016 1;14(6):469-471. Epub 2016 Dec 1.
    Singapore General Hospital, Singapore.
    A 62-year-old woman presented with a 2-year history of extensive, pruritic dermatosis over her face, trunk, and limbs. She was initially treated for psoriasis with methotrexate 5 mg twice weekly and topical clobetasol cream; however, her condition worsened, and she was admitted for generalized exfoliative dermatitis. Examination showed generalized erythema and scaling affecting her face (Figure 1A), chest (Figure 1B), back, and limbs. Read More

    Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 Revision of the World Health Organization Classification.
    J Formos Med Assoc 2016 Dec 18. Epub 2016 Dec 18.
    Department of Radiology, Chi-Mei Medical Center, Tainan, Taiwan.
    Background: Lymphoid neoplasms are heterogeneous and types of lymphoma vary in different geographic regions. In this study, we aimed at classifying the lymphoid neoplasms at our institution in Taiwan and to compare the relative frequency of various types of lymphoma in different countries.

    Methods: We retrospectively searched the files of patients diagnosed with lymphoma at our institution from 2000 to 2015 based on the 2016 Revision of the World Health Organization classification. Read More

    [Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas].
    Zhonghua Xue Ye Xue Za Zhi 2016 Nov;37(11):952-956
    Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemstasis of Ministry of Health, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
    Objective: To evaluate the efficacy of auto-HSCT and allo-HSCT in the treatment of high risk peripheral T cell lymphoma (PTCL). Methods: From July 2007 to July 2014, 60 cases of high risk PTCL were analyzed retrospectively. Results: All 60 patients were at high risk group (carried with IPI≥3), with a median age of 31 (12-58) years old. Read More

    The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
    Br J Haematol 2017 Mar 16;176(5):750-758. Epub 2016 Dec 16.
    Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnosed with PTCL-NOS (n = 180) or AITL (n = 141) between 1999 and 2015, were analysed. Failure-free survival (FFS) and overall survival (OS) were calculated from the time of first disease progression (FFS1, OS1), from second disease progression (FFS2, OS2) and from third progression (FFS3, OS3). Read More

    How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
    Br J Haematol 2017 Mar 16;176(6):851-866. Epub 2016 Dec 16.
    Institute of Pathology, University Hospital Lausanne and University of Lausanne, Switzerland.
    Peripheral T-cell lymphoma (PTCL), not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma (AITL) are the most frequent of more than 20 mature PTCL entities featuring a broad spectrum of morphological, immunophenotypic, molecular and clinical characteristics. Unfortunately, recent progress in understanding the (epi)genetic background of PTCL has not been met with similar advances in treatment. Thus, CHO(E)P [cyclophosphamide, doxorubicin, vincristine, and prednisone (plus etoposide)] remains standard first-line therapy. Read More

    The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
    Proc Natl Acad Sci U S A 2016 Dec 12;113(52):15084-15089. Epub 2016 Dec 12.
    The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada;
    Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at three hotspot arginine residues cause an enzymatic gain of function that leads to the production and accumulation of the metabolite 2-hydroxyglutarate (2HG), which contributes to the development of a number of malignancies. In the hematopoietic system, mutations in IDH1 at arginine (R) 132 and in IDH2 at R140 and R172 are commonly observed in acute myeloid leukemia, and elevated 2HG is observed in cells and serum. However, in angioimmunoblastic T-cell lymphoma (AITL), mutations are almost exclusively restricted to IDH2 R172, and levels of 2HG have not been comprehensively measured. Read More

    BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.
    Int J Hematol 2017 Apr 5;105(4):465-469. Epub 2016 Dec 5.
    Department of Hematology, Comprehensive Human, Biosciences, University of Tsukuba, Tennodai, Tsukuba, Ibaraki, Japan.
    BCL6, a master transcription factor for differentiation of follicular helper T (TFH) cells, is highly expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphomas (PTCL) containing tumor cells with TFH features. TET2, encoding an epigenetic regulator, is frequently mutated in AITL/PTCL. We previously reported that Tet2 knockdown mice developed T-cell lymphomas with TFH features. Read More

    T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach.
    J Clin Pathol 2017 Mar 28;70(3):187-201. Epub 2016 Nov 28.
    Haematological Malignancy Diagnostic Service, Centre for Molecular Pathology, The Royal Marsden Hospital, Sutton, London, UK.
    Accurate diagnostic interpretation of a lymphoid population composed predominantly of small T cells, together with smaller numbers of large B cells, with or without a nodular architecture, is a common problem faced by the histopathologist. The differential diagnosis of this histological pattern is wide, ranging from reactive conditions such as drug reactions and viral infections, through borderline entities such as immunodeficiency-related lymphoproliferative disorders to lymphomas. The latter includes entities where the large B cells are primarily neoplastic (classical and nodular lymphocyte-predominant Hodgkin lymphomas and T cell/histiocyte-rich large B cell lymphoma) as well as T cell lymphomas such as angioimmunoblastic T cell lymphoma where the large B cells represent an epiphenomenon and may or may not be neoplastic. Read More

    Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma.
    Int J Lab Hematol 2017 Feb 24;39(1):112-117. Epub 2016 Nov 24.
    Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
    Introduction: The prognostic value of serum ferritin level in patients with peripheral T-cell lymphoma (PTCL) remains unknown.

    Methods: We retrospectively analyzed clinical data from 78 consecutive patients with newly diagnosed PTCL that were treated with anthracycline-containing regimens between 1998 and 2011.

    Results: The patients consisted of 50 males and 28 females with a median age of 64 years (range, 16-83 years). Read More

    1 OF 41